ORIGINAL ARTICLE

IMPACT OF KHAT (CATHA EDULIS) CHEWING/USE ON HEART RATE AND BLOOD PRESSURE: A CRITICAL REVIEW

Zhi Xiong Chong¹, Mustafa Alshagga*, Khaled Ahmed Saed² and Saba Kassim³

¹Department of Biomedical Science, Faculty of Science, University of Nottingham Malaysia Campus, Semenyih, Malaysia
²Department of Surgery, Faculty of Medicine, Aden University, Yemen
³Taibah University Dental College and Hospital (TUDCH), Al-Madinah Al-Munawwarah, Saudi Arabia

Corresponding author:
*Mustafa Alshagga
Mustafa.al-shagga@nottingham.edu.my, Yamosta@gmail.com

ABSTRACT

Khat leaves chewing/use, which imparts amphetamine like effects on the user, is widely practiced in parts of Africa, the Arabian Peninsula, and among the diaspora communities from these regions. Basic clinical and epidemiological studies from different settings have reported associations of acute coronary syndrome, heart failure, and cardiomyopathy, with khat chewing/use. This review aims to analyse the current evidence of the impact that khat, or its active constituent, cathinone, has on the cardiovascular system (CVS), particularly in two parameters, heart rate (HR) and blood pressure (BP). Subsequently, the possible mechanism of actions of how khat impacts these cardiovascular parameters is discussed, and different studies’ findings are summarised appropriately. The analysis of literature suggests that khat could influence HR and BP by most likely causing tachycardia and hypertension and the impacts might be dose-dependent and time-dependent. However, most of the studies involved different species and study designs, and had different limitations. Additionally, the underlying mechanisms of khat effects on these CVS parameters remain unclear. Therefore, more studies are needed to further support the current evidence of the impacts that khat has on the CVS parameters of HR and BP.

Keywords: Khat, cardiovascular system (CVS), heart rate, blood pressure, cathinone, Review

INTRODUCTION

Khat or Catha edulis is a common recreational drug used/chewed in Africa and Arabic regions especially in Yemen, Ethiopia and Somalia. It has a slightly sweet taste and an aromatic smell that attracts people to chew it for recreational purpose¹. The main khat components include cathinone, cathine, norephedrine, and pseudoephedrine. Cathinone and cathine are the most active bio-compounds of khat². Cathinone has structural and functional similarities to indirectly-acting sympathomimetic agents like amphetamine. Excessive khat consumption is related to mood disorders, metabolic disorders, and cardiovascular diseases ²⁴. Frequent khat use is also suggested to have negative impacts on the socio-economic function of an individual, as well as on the country at large¹.

For the past 25 years, numerous studies have shown that excessive khat use could lead to acute coronary syndrome, cardiomyopathy, and heart failure ⁴. Structural mimicry between khat constituents and indirectly-acting sympathomimetic agents allows it to activate the sympathetic nervous system, thereby elevating the blood pressure and the heart rate ³. Specifically, the impact of khat and ethanolic extracts of its active constituent, cathinone, on the cardiovascular system (CVS) parameters of heart rate (HR) and blood pressure (BP) have been reported from different settings¹⁻¹³. However, there is a gap in knowledge to substantiate the aforementioned findings. Therefore, this review aimed to assess and summarise the impacts of khat on HR and BP.

METHODS

A systematic database search was performed in March 2017 to look for relevant articles on the impact of khat on the cardiovascular system (CVS), and the study method (Figure 1) was adopted from previous systematic review studies ²⁻⁷. Four electronic databases, namely PubMed, NUsearch-UK, Web of Science and Science Direct, were employed for the literature search. Khat-related keywords like Catha edulis, khat, qat, mirra and murungu, and Khat bio-substance-related terms like cathinone, norephedrine, pseudoephedrine and cathine were used during the search. CVS parameters which were used in the search included heart rate, tachycardia, blood pressure, hypertension, and myocardial infarction. All relevant quantitative studies, either cross-sectional or experimental studies, and any clinical trials that involved animals or humans were included. The excluded studies were systematic reviews, case reports, letters to the editor, articles written in languages other than English, duplicated articles, khat studies on non-CVS parameters, and any other articles which were unrelated to both khat and CVS.
### RESULTS

**The effects of Khat on Heart Rate**

Khat has been shown to increase the heart rate (Appendix table 1) in some animal and human studies. In one animal study, male Wistar rats (n=10) were supplied with 3g/kg of the rat's weight (equivalent to 0.5g/kg consumption among khat chewers) of oral khat leave extract. Maximal heart rate was recorded at 40 minutes post-khat administration (study duration: 1 hour), accompanied by decreased atrial depolarisation (PR waves) and prolonged ventricular repolarisation (QT waves) intervals. The increase in the heart rate was significant (p<0.05) when comparing control and khat-treated rats and the heart rate differed by 5 to 12.8% between both groups at different intervals. Khat-induced tachycardia were also reported in human studies using the active compound of khat (cathinone). In a human placebo-controlled study (n=6, male) subjects were administered cathinone at a concentration of 0.5mg/kg, and the subjects' heart rates were observed for 8 hours after administration. Compared to the control, heart rate among cathinone-treated group was very significantly elevated (p<0.001).

Another human study used cathinone concentrations of 0.8mg/kg, and the study duration was 9 hours but the increase in the heart rate among cathinone-treated group was insignificant (p>0.05). Both the animal and human studies have been recorded the heart rate at regular intervals after drug administration. Regardless of the variation in dosage, khat leave extracts and cathinone have been shown to increase heart rates in both animal and human. This possibly suggests that cathinone is one of the primary bioactive compounds of khat that causes an acceleration of heart rate. The main difference between the animal and human studies was found in the timing of the onset of the increasing heart rate. The maximal heart rate was noted at 2 hours post-khat administration in the human study compared to the 40 minutes in the rat study. Literature has suggested that plasma cathinone level usually peaks at 2 to 3 hours after oral administration in human, and so it is expected that the maximal heart rate was observed at 2 hours post-cathinone administration. One possible reason to explain the faster onset of maximal heart rate in rats is the higher dose of the extract which may have caused a speedier drug absorption and distribution rate in rats than in human. There are probably additional components of khat extract that could affect heart rate, or it may also be possible that some other unclear drug-body interaction exists that could have led to a quicker drug absorption and action, which might be interesting to study further.

An experimental crossover human study has been carried out in Saudi Arabia (n=21; unspecified gender) showed that chewing 45g of khat leaves significantly induced tachycardia (p<0.05) among the participants during and after exercise compared to placebo ingestion. The mean heart rate ± standard deviation (SD) of the khat-treated group was 15.8 ± 11.5 beats per minute (bpm) higher than the control group. This finding indicates an additional impact of khat on heart rate, over the accelerated heart rate induced by...
exercise. A crucial limitation of the study was the inability to differentiate the baseline heart rate of the participants, and an absence of information on any history of life-related stressors and exercise tolerance before khat administration. Regular exercise is well-known to accelerate the heart rate via sympathetic nervous system activation, compared to placebo in many studies, but in the long-term, exercise actually lowers both stress and heart rate.

Another cross-sectional human study (n=664; mixed gender) in Ethiopia has shown that the mean heart rate among khat chewers (76.3 ± 11.5 bpm) was significantly higher (p<0.05) than non-chewers (73.9 ± 12.6 bpm). Even though this study has used a validated questionnaire and a consistent data collection method, it could still be biased based on the self-reporting of results. Additionally, the number of participants who have habits of smoking and drinking coffee were significantly higher among the chewers than the non-chewers. Since the half-life of caffeine ranges from 2 to 12 hours, and cathine and cathine half-lives are 1.5 ± 0.8 hours and 5.2 ± 3.4 hours, respectively, it is unclear whether it was caffeine or khat that induced the tachycardia. Also, it is unclear whether the chewers consumed similar khat doses every day, and the heart rate measurements were taken between 8:30am and 6:30pm, independent of the timing of khat ingestion. It is unclear if the difference in heart rate between khat chewers (76.3 ± 11.5 bpm) and non-chewers (73.9 ± 12.6 bpm) would have a tangible clinical significance rather than just statistical significance.

Studies that attempted to explore the mechanism of action of khat effect on heart rate are scant. A human, double-blinded, 3 arm cross-over, placebo-controlled study (n=63; all male) involving khat, indoramin (selective α1-blocker) and atenolol (selective β1-blocker), showed that atenolol could potentially reduce the significantly elevated heart rate induced by khat, but could not do so for elevated heart rates as a result of indoramin administration. This suggests that heart rate acceleration among khat chewers is mediated by β1-adrenoceptors rather than α1-adrenoceptors. Once activated, a G-protein coupled receptor (Gs-coupled β1-adrenoceptor) dissociates, activates adenyl cyclase (AC), and increases cytosolic cyclic adenosine monophosphate (cAMP) which activates Ca²⁺ channels. This Ca²⁺ influx promotes actin-myosin interactions, increases heart contraction forces, and causes tachycardia. Definitive knowledge of a direct effect of khat or cathine at the receptor level is lacking. Nevertheless, the structural similarity between cathine and amphetamine allows for cathine to function as an indirectly-acting sympathomimetic agent. Amphetamine could promote the release of monoamines and reduces their reuptake, thus, increasing dopamine, noradrenaline and serotonin levels in the synaptic cleft. This causes sympathetic over-activity and tachycardia. So, if cathine could act like amphetamine in causing sympathetic over-activity, this would highlight a central, rather than peripheral effect of khat or cathine on heart rate. Moreover, the standard dose of khat used in the 3 arms probably neglected the differential affinity of adrenergic receptors for sympathomimetics.

On the contrary, an organ bath study (90 seconds) using male albino rabbits heart tissue (n=6) showed that khat extract significantly (p<0.05) decreased heart rate in a concentration- and time-dependent manner by exerting negative inotropic and chronotropic effects. Compared to the rat and human in vivo studies that showed khat-induced tachycardia, this ex vivo study used 50, 100 and 250mg/mL of khat extracts (extracted using 70/30% water: ethanol). It could be the difference in the study design and the variation in the khat concentration used that would explain why bradycardia was observed. The exact mechanism that caused this phenomenon is unclear, but Al-Hashem et al. suggested that khat might alter membrane ion movements (Ca²⁺, Na⁺) that can delay depolarisation, thus causing bradycardia, which reduces coronary perfusion and induces myocardial necrosis. Khat-induced noradrenaline release could indirectly trigger α1-adrenoceptor-dependent coronary vasoconstriction by promoting Ca²⁺ ion entry into vascular smooth muscle, thus worsening myocardial perfusion and further depressing cardiac contractility. Several case reports also have suggested a possible association between khat consumption and coronary vasoconstriction. Major drawbacks of the ex vivo study include the use of the whole khat extract without simultaneous comparison to the khat active compound (cathine), in addition to the presence of tannins and flavonoids in khat extract which probably have inhibitory cardiac effects by anti-cholinergic or anti-histaminic mechanisms.

Generally, based on the different reports in the literature in which the relationships between khat, or cathine, consumption and heart rate have been studied, it is shown that khat, or cathine, plays some kinds of role in accelerating the heart rate. However, all these studies did not explain in detail the impact of khat on stroke volume, myocardial contractility and cardiac output, or identify secondary neuro-hormonal mechanisms that could elicit changes in heart rate. In addition, most reported studies have limitations such as the use of different samples like khat leaves extracts vs cathine active compounds, different compounds concentration, short study duration (generally ranging from several hours to several months), small sample size (generally n=100), lack of repeated study results, and recruitment of only males in both rat and human studies, which raises gender bias concerns. Any or all of these
limitations would probably affect the various study findings. The effects of Khat on Blood Pressure
As noted in the aforementioned studies, khat, or its active alkaloid cathinone, influences both heart rate and contractility, and therefore, increases in cardiac output, which is a major determinant of mean systolic blood pressure. All pooled studies in this review are summarised (Appendix table 2). In Ethiopia, four cross-sectional studies were reported, including a very large-scale study (n=4001; mixed gender) and another two smaller studies (n=667; mixed gender) and (n=422; all male). An additional study (n=330; mixed gender) has focused on the population in Eastern Ethiopia. Most studies showed that khat could significantly (p<0.05) elevate diastolic blood pressure, particularly in non-chewers (p<0.05) only in one study (AOR:14.95; CI: 5.49-40.66), while insignificant systolic blood pressure elevations were observed in the earlier study (beta coefficient (B) of 1.6) and another mentioned study also showed insignificant increase in the systolic blood pressure among khat chewers (116.9 ± 17.8 mmHg) compared to non-chewers (116.1 ± 16.8 mmHg). The insignificant systolic blood pressure elevations were not explored further. However, diastolic blood pressure has shown in most studies to be elevated by khat, which is more useful in the assessment of peripheral blood resistance, thereby causing high blood pressure. Khat chewing is also associated with an increased risk of hypertension (AOR: 1.98; CI: 2.99-5.46). In a study conducted in Yemen, involving undergraduate medical students (n=100; mixed gender), blood pressure was shown to fluctuate among the khat chewers.

On the other hand, an animal study involving male Wistar rats (n=10) that were administered 3g/kg rat’s weight of khat leave extract, and two placebo-controlled human studies (n=6; all male) which used 0.5mg/kg and 0.8mg/kg cathinone concentration, have all shown that khat, or cathinone, could possibly significantly increase (p<0.05) blood pressure in vivo, in both time- and dose-dependent manners. For the rat study, the SBP among khat-treated rats was 8.1 to 26.3% higher than the SBP of the control while the DBP was 22 to 53.5% higher in the khat-treated group. The mean SBP and DBP differences in the two human trials were not explained further. The possible mechanism of how khat induces hypertension was suggested by a human study (n=63; all male) in 2005. In that study, it was shown that khat-induced hypertension could be antagonized significantly (p<0.05) by atenolol (selective β1-blocker) but not indoramin (selective α1-blocker). This suggests that khat-induced hypertension is associated with β1-adrenoceptor-mediated tachycardia. Increases in sympathetic activity after khat, or cathinone, administration probably could be elucidated by an increase in renin secretion from the kidney, and an increase in the activity of the renin-angiotensin aldosterone system (RAAS). The RAAS activation might cause increase in blood volume and this might increase the peripheral vascular resistance reflected in elevated diastolic blood pressure.

Another two organ bath experiments (n=unspecified, both used guinea pig tissue) showed that cathinone could significantly increase (p<0.05) coronary vasoconstriction in a dose-dependent manner. Cathinone was shown to cause peak coronary vasoconstrictions of the guinea pig by 56.5 ± 13.8% and 56.5 ± 4.2% when 1mM and 300µM of cathinone were administered respectively. It was unclear why almost similar peak vasoconstriction was produced when two different cathinone concentrations were given, but it could imply that 300µM is the maximal cathinone concentration that could cause peak vasoconstriction and further increasing the cathinone concentration would not produce more vasoconstriction. On the other hand, it was postulated that khat-induced vasoconstriction is not mediated via α1-adrenoceptors or indirect-acting sympathomimetic action, but could be related to the release of endogenous vasoconstrictors like endothelin and angiotensin, although the mechanism was unclear. This suggests the possibility that the khat-induced vasopressor effect could be mediated by an endothelin-induced release of prostaglandin and thromboxane A2 (vasoconstriction effects). Further pharmacologic and in vivo studies will be needed to verify this hypothesis.

Interestingly, a study conducted in Yemen (n=74; mixed gender) suggested that khat would reduce blood pressure significantly (p<0.05) in which the baseline SBP among chewers was 105.2 ± 1.9 mmHg compared to non-chewers 105.8 ± 1.8 whereas the baseline DBP was 68.2 ± 1.6 among chewers compared to 71.6 ± 1.6 among non-chewers. To the best of our knowledge, this is the only report that suggests such a possibility. This study did not explain the underlying mechanism, but instead, correlated reduced cognitive function and blood pressure to khat usage. In this study, the khat consumption habits of the participants were standardized (chewed 5 hours/day, 5 times/week for almost 6 years), but the consumption dosage was unclear. Therefore, it could be the consumption dosage that explained why khat led to lowered blood pressures.
Different khat, or cathinone, concentrations might be associated with different selectivity towards the adrenergic receptor. In this study, it could be the activation of the α2-adrenergic receptors that led to sympathetically inhibited and hypotension 19. Since the reported usual cathinone concentration that is associated with hypertension is 0.5-0.8mg/kg 8,9, it might be that a lower or higher cathinone concentration favours α2-adrenergic receptor occupancy, but more studies will be needed to validate this hypothesis.

Many of the reported studies suggested possible associations between khat consumption and hypertension. However, most of these studies only focused on the Yemeni and Ethiopian populations5,20,32-34,38 which did not take into consideration potential inter-population variations 41. Most cross-sectional studies 20,32-34,38 did not really standardize or mention the khat consumption habits or usages among the participants, which is significant because different dosages consumed might affect blood pressure differently 42.

There were some studies44 in which the investigators ensured that the participants did not smoke or drink caffeine before their blood pressure measurements, since these substances could have potentially affected the results 43, but other studies 20,32,33,38 did not document that these factors had been taken into consideration. The timing of the blood pressure measurements could have also affected the validity of the results 44. One study measured the blood pressure independent of the timing of khat consumption 20, while another study measured the blood pressure at least 14 hours-post khat administration 38 which is problematic because the khat plasma concentration would likely have dropped drastically so long after administration due to drug metabolism 45. In another two studies 32,33, it is unclear when the blood pressure was taken. As for the study duration and sample size (n), cross-sectional studies generally employed a large sample size (n) and a long study duration, with the exception of the reported animal and human experimental studies 1,8,11,40 which used relatively small n and short study durations. Most of the cross-sectional studies also had participants of both genders in their studies, with the exception of one cross-sectional study 33. The reported animal and human non-cross-sectional studies 8,11, only males were employed and this likely caused gender bias 39.

CONCLUSION AND FUTURE DIRECTIONS

This review comprehensively summarises and assesses the findings from different studies where khat had been suggested to influence the heart rate and blood pressure, but the evidences were inconclusive due to the different studies’ limitations. Future cross-sectional studies should focus on multiple ethnicities, as current studies mainly focus on African and Arabic populations. Other parameters like khat chewing/use history, blood pressure measurement techniques, and timing of blood pressure measurement should be standardized to ensure reliability of the results.

Animal and human experimental studies should focus on obtaining participant subjects of both genders, in order to avoid the inability to standardize or generalize results due to gender biases. It is also advisable to use larger sample sizes and longer study durations to test the impact of khat in vivo. There are still some gaps to be filled in the literature, with regard to the exact mechanism of how khat affects different CVS parameters. Therefore, more studies should be done in the future to further establish the relationship between khat and adverse cardiovascular outcomes, as well as to identify the exact underlying molecular mechanisms.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

REFERENCES


**APPENDIX**

Table 1: A summary of the khat influences on the cardiovascular system based on human studies/reports (n=10).

<table>
<thead>
<tr>
<th>Human Studies / Reports</th>
<th>Gender/sample size (n), study design, dose (Study duration)</th>
<th>Khat effects on the cardiovascular system (CVS)</th>
<th>Study strengths and weaknesses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Heart rate (beats /min)</td>
<td>Blood pressure (mmHg)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SBP</td>
<td>DBP</td>
</tr>
<tr>
<td>Brenneisen et al. 1990</td>
<td>M (n=6), placebo-controlled balanced experimental study, 0.5mg/kg cathinone oral capsule or placebo (8-hours study).</td>
<td>↑ (S)</td>
<td>↑ (S)</td>
</tr>
<tr>
<td>Widler et al. 1994</td>
<td>M (n=6), double-blinded placebo-controlled balanced study, khat leaves extracts containing 0.8mg/kg cathinone or placebo (10-hours study).</td>
<td>↑ (NS)</td>
<td>↑ (S)</td>
</tr>
<tr>
<td>Hassan et al. 2005</td>
<td>M (n=63), double-blinded 3 arm cross-over placebo controlled study, khat dose standardised but dosage was unclear + either placebo or 50mg atenolol or 25mg indoramin (4-months study).</td>
<td>↑ (S)</td>
<td>↑ (S)</td>
</tr>
<tr>
<td>Tesfaye et al. 2008</td>
<td>M and F (n=4001), cross-sectional study, 20% chewers vs 80% chewers (Study duration not specified).</td>
<td>-</td>
<td>↑ (NS)</td>
</tr>
<tr>
<td>Laswar and Darwish 2009</td>
<td>M and F (n=100), cross-sectional study, 54% chewers vs 46% non-chewers, study done in year 2004.</td>
<td>-</td>
<td>F (NS)</td>
</tr>
<tr>
<td>Getahun et al. 2010</td>
<td>M and F (n=667), cross-sectional study, 50.3% chewers vs 49.7% non-chewers (Study duration not specified).</td>
<td>↑ (S)</td>
<td>↑ (NS)</td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Study Design</td>
<td>Key Findings</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------------------</td>
<td>-------------------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Birhane and Birhane 2014</td>
<td>M (n=422)</td>
<td>Cross-sectional study</td>
<td>All chewers (9-month study)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ (S)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ (S)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Nakajima et al. 2014</td>
<td>M and F (n=74)</td>
<td>Cross-sectional study</td>
<td>49 khat chewers vs 25 non-chewers</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ (S)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↓ (S)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Sallam et al. 2016</td>
<td>Gender unspecified (n=21)</td>
<td>Experimental crossover study</td>
<td>33ml placebo juices or 33ml juices + 45g ground khat leaves (3-months study)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ (S)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Seifu et al. 2017</td>
<td>M and F (n=330)</td>
<td>Cross-sectional study</td>
<td>91.81% khat chewers vs 8.19% non-chewers (1-month study)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Khatraised BP but it was unclear whether it raised SBP, DBP or both.</td>
</tr>
</tbody>
</table>

All the human studies/reports were arranged according to chronological order.

↑: means increase; ↓: means decrease.


*Khat and heart rate theme; **Khat and blood pressure theme
Table 2: A summary of the khat impacts on the cardiovascular system based on animal studies/reports (n=4).

<table>
<thead>
<tr>
<th>Author(s), year</th>
<th>Study model/gender, study design (sample size, n), dose (study duration)</th>
<th>Khat effects on the cardiovascular system (CVS)</th>
<th>Study strengths and weaknesses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al-Motarreb and Broadly 2003</td>
<td>Dunkin-Hartley guinea-pigs/M, experimental organ baths (no. of baths used not clearly stated), cathinone 0.01-1000μg+ use of other sympathomimetic and its blockers (1-day study).</td>
<td>Heart rate (beats /min)</td>
<td>Blood pressure (mmHg)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SBP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baker et al. 2007</td>
<td>Guinea pig/M, experimental organ baths (no. of baths used not clearly stated), cathinone 3-300μM + use of other sympathomimetic and its blockers (1-day study).</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Al-Hashem et al. 2012</td>
<td>White albino rabbit/M, experimental organ baths (n=6), 50, 100 and 250mg/ml khat leaves extracts (90 minutes).</td>
<td>↓ (S)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Al-Hashem and Shatoor 2012</td>
<td>Wistar rat/M, experimental (n=10 for control and n=10 for khat leaves extracts treated group), oral dose of 3mg/kg (60 minutes).</td>
<td>↑ (S)</td>
<td>↑ (S)</td>
</tr>
</tbody>
</table>

All the animals studies/reports were arranged according to the chronological order.

↑ means increase; ↓ means decrease.

BP: Blood pressure, HR: Heart rate, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, M: Male, F: Female, S: Significant, NS: Not significant, n: Sample size, ECG: Electrocardiogram

*a-Khat and heart rate theme; b-Khat and blood pressure theme